Basic Information
| LncRNA/CircRNA Name | PTCSC3 |
| Synonyms | NA |
| Region | GRCh38_14:36136108-36176468 |
| Ensemble | ENSG00000259104 |
| Refseq | NR_049735 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | anaplastic thyroid cancer |
| ICD-0-3 | C73 |
| Methods | qPCR, Western blot, RIP, in vitro knockdown etc. |
| Sample | cell lines (FTC 238,FTC 133), ATC and FTC tissues |
| Expression Pattern | down-regulated |
| Function Description | LncRNA PTCSC3 was low-expressed in ATC tissues and cells.Over-expressed PTCSC3 inhibited the drug resistance of ATC to doxorubicin. PTCSC3 negatively regulated STAT3, and STAT3 promoted expression of INO80. PTCSC3 regulated INO80 through STAT3. PTCSC3 suppressed stem cells properties and drug resistance of ATC to doxorubicin.CLncRNA PTCSC3 inhibits INO80 expression by negatively regulating STAT3,and thereby attenuating drug resistance of ATC to chemotherapy drug doxorubicin. |
| Pubmed ID | 29561707 |
| Year | 2018 |
| Title | LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. |
External Links
| Links for PTCSC3 | GenBank HGNC NONCODE |
| Links for anaplastic thyroid cancer | OMIM COSMIC |